Home/Glycadia Pharmaceuticals/John Brennan, PhD

JB

John Brennan, PhD

Chief Development Officer

Glycadia Pharmaceuticals

Therapeutic Areas

Diabetes Nephrology Ophthalmology Cardiovascular

Glycadia Pharmaceuticals Pipeline

Drug	Indication	Phase
GLY-230	Diabetic complications (Nephropathy focus)	Phase 2
GLY-220	Diabetic macrovascular disease	Pre-clinical
ES12 mAb	Diabetic macrovascular disease	Pre-clinical
A717 mAb	Diabetic microvascular disease	Pre-clinical

Leadership Team at Glycadia Pharmaceuticals

Patrick M. O’Keefe

Chief Executive Officer

Sarabjit S. Ashta

Chief Business Officer

Clyde Shearman, PhD

President & Chief Scientific Officer

View full Glycadia Pharmaceuticals profile